Gastroscopic Esophageal Prick Test in adult Eosinophilic Esophagitis Patients: a pilot study

Completed

• Conditions: allergic esophagitis; Eosinophilic esophagitis; 10017969; 10001708

• Registration Number: NL-OMON42606
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

Patients
-Previous diagnosis of active EoE confirmed by histopathology e.g. presence of >15 eosinophilic granulocytes per high power field (hpf) in mid or proximal esophageal biopsies
-Macroscopic disease remission or significant mucosal healing after four weeks of treatment with an elemental or elimination diet
-Written informed consent
-Age 18 * 75 years;Healthy control group
- Written informed consent
- Age 18 * 75 years
- Absence of atopic diseases
- Absence of gastrointestinal symptoms

Exclusion Criteria

Patients
- Inability to stop topical corticosteroids
- Inability to stop beta-blockers and ACE inhibitors
- Use of oral or systemic antihistaminics, oral cromoglicates, systemic corticosteroids, leukotriene inhibitors, or monoclonal antibodies, in the month preceding the study
- Proven gastroesophageal reflux disease or other cause for esophageal eosinophilia
- History of peptic ulcer disease
- History of Barrett*s esophagus
- History of GI cancer
- History of GI tract surgery (except appendectomy)
- ASA class III, IV or V
- History of anaphylaxis
- History of a severe systemic reaction to previous allergy tests (grade 3 or 4);Healthy controls
- History of atopic diseases
- Inability to stop beta-blockers and ACE inhibitors
- Use of oral or systemic antihistaminics, oral cromoglicates, systemic corticosteroids, leukotriene inhibitors, or monoclonal antibodies, in the month preceding the study
- Proven gastroesophageal reflux disease or other cause for esophageal eosinophilia
- History of peptic ulcer disease
- History of Barrett*s esophagus
- History of GI cancer
- History of GI tract surgery (except appendectomy)
- ASA class III, IV or V
- History of anaphylaxis
- History of a severe systemic reaction to previous allergy tests (grade 3 or 4)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. Visible immune response to allergens injected into the esophageal mucosa,<br /><br>defined as wheal and flare reaction.<br /><br><br /><br>2. In vitro immune response of esophageal mucosal tissue in culture medium to<br /><br>added allergenic solutions, defined as release of inflammatory cytokines,<br /><br>histamine and tryptase.</p><br>